Binder Bio Group

Binder Bio Group is a clinical-stage biotechnology company founded in 2015 and headquartered in Shenzhen, China. The company specializes in the development of next-generation immune cell therapies, specifically Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor T-cell (TCR-T) therapies, for the treatment of hematological and solid tumors. Its pipeline includes candidates targeting a wide range of antigens such as CD19, BCMA, NY-ESO-1, and Mesothelin, with several programs currently in Phase 1/2 clinical trials. Binder Bio Group operates a comprehensive immunotherapy industrial chain, including GMP-compliant manufacturing facilities and collaborations with the Chinese Academy of Sciences and major hospitals across China.